aibioUnsubscribe
One click and you get no more email from us. Full reading access on this browser ends too, and you can rejoin whenever you like.
Friday, October 23, 2026Biotech Investor Relations News
- Debt Financing Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J
- Debt Financing Repligen announces $1.0 billion private convertible notes transaction
- Company Updates PTC reports third-quarter 2026 revenue of $358 million and raises product guidance
- Company Updates Processa clears VT-7208 CSU IND and names a new executive chair
- Company Updates Kiora in-licenses late-stage KIO-401 for retinal artery occlusion
- Company Updates Azitra expands ATR-04 trial to rash from KRAS and MEK inhibitors
- Debt Financing FOXO to buy Ludwig Enterprises preferred stock with majority voting power
- Company Updates Dermata enrolls first participant in Tome Clearing Treatment trial
- Legal Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena
- Legal Viking and Ligand dispute VK2809 license termination in San Diego court
- Legal Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit
- Legal Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits
- Legal Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028
- Debt Financing Altimmune draws $10.0 million third tranche from Hercules loan facility
- Legal European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer
- Financings INmune Bio raises $4.50 million in registered direct offering with warrants